GENFLEET-B (02595.HK): Repurchases 872,000 H shares, about 0.227% of issued share capital
NewTimeSpace News: On 21 September 2026, GenFleet Therapeutics (Shanghai) Inc. (stock code: 2595) published a voluntary announcement on the progress of its share repurchase.
The announcement stated that, as at 18 September 2026, the Company had conducted a series of H share repurchases on the Stock Exchange, repurchasing a total of 872,000 H shares, representing approximately 0.227% of the Company's total issued share capital as at the date of the announcement. The Company stated that it may continue to implement its 2026 H share repurchase plan after assessing market conditions. Shareholders and potential investors are reminded that share repurchases will depend on market conditions and are at the absolute discretion of the Board, and that no assurance can be given as to the timing, quantity or price of any share repurchase.
NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.
- GENFLEET-B (02595.HK): Phase II Data of GFH375 in Treated NSCLC Presented at WCLC, Confirmed ORR 52.1%
- GENFLEET-B (02595.HK): two first-in-class pancreatic cancer combination therapies of GFH375 advance to Phase II studies
- GENFLEET-B (02595.HK): Phase III study of world's first oral KRAS G12D inhibitor for NSCLC initiated; second registrational clinical study of GFH375 completes first patient enrolment
- GENFLEET-B (02595.HK) plans to issue in total 13.6 million shares by placement, with estimated net proceeds of HKD 466.9 million
- GENFLEET-B(02595.HK) closed 9.28% higher, the Hang Seng Pharmaceuticals & Biotechnology Sector saw divergent trends